Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708045 | 1.00 | CYP2C19 (0.35) | CYP2C19ALDH1A1PDE2ASMN1; SMN2KMT2A | |
| SCHEMBL25207482 | 0.77 | KMT2A (0.30) | KMT2A | |
| SCHEMBL2627828 | 0.76 | CYP2C19 (0.40) | CYP2C19ALDH1A1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL30282364 | 0.76 | CA2 (0.44) | — | |
| SCHEMBL28956162 | 0.76 | CA2 (0.44) | — | |
| SCHEMBL31708108 | 0.75 | PDE2A (0.51) | ALDH1A1PDE2AKDM4E | |
| SCHEMBL31708065 | 0.75 | LMNA (0.42) | CYP2C19ALDH1A1PDE2ASMN1; SMN2KMT2A | |
| SCHEMBL25239087 | 0.73 | PDE2A (0.33) | PDE2ASMN1; SMN2 | |
| SCHEMBL31691911 | 0.73 | CYP2C19 (0.38) | CYP2C19ALDH1A1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL30282397 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | CYP2C19 2415/4885ALDH1A1 1097/4885PDE2A 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.